Henlius 2025 Annual Results Showcase Unprecedented Revenue and Profit Growth Amidst Global Expansion Efforts Henlius shares impressive 2025 annual results showing significant revenue growth, profit increase, and advancements in global biopharmaceutical operations.

Henlius 2025 Annual Results Showcase Unprecedented Revenue and Profit Growth Amidst Global Expansion Efforts #China #Shanghai #Serplulimab #Henlius_Biotech #HERCESSI

Henlius Unveils 'Globalisation 2.0' Strategy at JPM 2026 Conference with Long-Term Innovation Roadmap At the JPM 2026, Henlius detailed its 'Globalisation 2.0' strategy aimed at innovative healthcare developments for the global market by 2030.

Henlius Unveils 'Globalisation 2.0' Strategy at JPM 2026 Conference with Long-Term Innovation Roadmap #USA #San_Francisco #Henlius_Biotech #Globalisation_2.0 #Innovation_Roadmap

Henlius Unveils Ambitious Globalisation 2.0 Strategy at JPM 2026 Conference At the J.P. Morgan Healthcare Conference 2026, Henlius unveiled its Globalisation 2.0 strategy, forecasting a robust pipeline and international growth across various therapeutic areas.

Henlius Unveils Ambitious Globalisation 2.0 Strategy at JPM 2026 Conference #United_States #San_Francisco #Henlius_Biotech #Jason_Zhu #Globalisation_2.0

Henlius Reveals Ambitious Globalization Strategy and Innovation Plans at JPM 2026 At the recent J.P. Morgan Healthcare Conference, Henlius shared its Globalisation 2.0 strategy along with a comprehensive innovation blueprint aimed at future growth.

Henlius Reveals Ambitious Globalization Strategy and Innovation Plans at JPM 2026 #United_States #San_Francisco #Henlius_Biotech #Jason_Zhu #Globalisation_2.0

Henlius Biotech's HLX22 Receives Orphan Drug Designation for Gastric Cancer Treatment in the U.S. Shanghai Henlius Biotech announces that the FDA has granted Orphan Drug Designation to HLX22, its promising anti-HER2 antibody, for gastric cancer treatment.

Henlius Biotech's HLX22 Receives Orphan Drug Designation for Gastric Cancer Treatment in the U.S. #China #Shanghai #Henlius #Henlius_Biotech #HLX22

Henlius and Dr. Reddy's Sign Licensing Agreement for HLX15 to Expand in Europe and the US Henlius Biotech and Dr. Reddy's Laboratories have signed a licensing deal for HLX15, a Daratumumab biosimilar, to broaden market presence in Europe and the USA.

Henlius and Dr. Reddy's Sign Licensing Agreement for HLX15 to Expand in Europe and the US #China #Shanghai #Dr._Reddy's #Henlius_Biotech #Daratumumab